** Shares of drug developer PTC Therapeutics PTCT.O fall ~20% to $40 premarket
** Co says its experimental drug to treat Huntington's disease met the main goal of a mid-stage study
** Huntington's is a rare neurological disease which impairs a person's ability to think, feel and move
** The drug, PTC518, helped significantly lower levels of a mutated protein in blood that causes the disease - PTCT
** "Stock has rebounded into the data so some may have been looking for indisputable results, but overall we believe the initial data looks to maintain the promise of the program, which over time we believe should be a win," said RBC Capital analysts
** Up to last close, stock up ~11% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.